Meningioma: International Consortium on Meningiomas consensus review on scientific advances and treatment paradigms for clinicians, researchers, and patients
Justin Z Wang,Alexander P Landry,David R Raleigh,Felix Sahm,Kyle M Walsh,Roland Goldbrunner,Leeor S Yefet,Jörg C Tonn,Chloe Gui,Quinn T Ostrom,Jill Barnholtz-Sloan,Arie Perry,Yosef Ellenbogen,C Oliver Hanemann,Gerhard Jungwirth,Michael D Jenkinson,Ghazaleh Tabatabai,Tiit I Mathiesen,Michael W McDermott,Marcos Tatagiba,Christian la Fougère,Sybren L N Maas,Norbert Galldiks,Nathalie L Albert,Priscilla K Brastianos,Felix Ehret,Giuseppe Minniti,Katrin Lamszus,Franz L Ricklefs,Jens Schittenhelm,Katharine J Drummond,Ian F Dunn,Omar N Pathmanaban,Aaron A Cohen-Gadol,Erik P Sulman,Emeline Tabouret,Emelie Le Rhun,Christian Mawrin,Jennifer Moliterno,Michael Weller,Wenya Linda Bi,Andrew Gao,Stephen Yip,Maximilian Niyazi,International Consortium on Meningiomas (ICOM),Kenneth Aldape,Patrick Y Wen,Susan Short,Matthias Preusser,Farshad Nassiri,Gelareh Zadeh
DOI: https://doi.org/10.1093/neuonc/noae082
2024-10-03
Abstract:Meningiomas are the most common primary intracranial tumors in adults and are increasing in incidence due to the aging population and increased access to neuroimaging. While most exhibit nonmalignant behavior, a subset of meningiomas are biologically aggressive and are associated with treatment resistance, resulting in significant neurologic morbidity and even mortality. In recent years, meaningful advances in our understanding of the biology of these tumors have led to the incorporation of molecular biomarkers into their grading and prognostication. However, unlike other central nervous system (CNS) tumors, a unified molecular taxonomy for meningiomas has not yet been established and remains an overarching goal of the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy-Not Official World Health Organization (cIMPACT-NOW) working group. Additionally, clinical equipoise still remains on how specific meningioma cases and patient populations should be optimally managed. To address these existing gaps, members of the International Consortium on Meningiomas including field-leading experts, have prepared this comprehensive consensus narrative review directed toward clinicians, researchers, and patients. Included in this manuscript are detailed overviews of proposed molecular classifications, novel biomarkers, contemporary treatment strategies, trials on systemic therapies, health-related quality-of-life studies, and management strategies for unique meningioma patient populations. In each section, we discuss the current state of knowledge as well as ongoing clinical and research challenges to road map future directions for further investigation.